美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Avalyn Pharma

34.98

+1.414.20%

盤後：34.980.00000.00%16:10 EDT

成交量：49.41萬

成交額：1,733.19萬

市值：15.51億

市盈率：-15.01

高：36.42

開：33.40

低：33.40

收：33.57

52周最高：40.17

52周最低：24.15

股本：4,433.31萬

流通股本：1,666.67萬

量比：2.53

換手率：2.96%

股息：- -

股息率：- -

每股收益(TTM):-2.3300

每股收益(LYR):-87.7434

淨資產收益率：-68.34%

總資產收益率：-41.74%

市淨率：3.89

市盈率(LYR):-0.40

資料載入中...

總覽公司新聞資訊公告

概念

no data

沒有相關數據

資金流向

資金流入：

資金流出：

新聞資訊

Avalyn完成AP01（吸入性吡非尼酮）針對進展性肺纖維化患者的2b期Mist試驗目標入組

Avalyn Pharma 將公布AP01（吸入性吡非尼酮）治療肺纖維化的更多長期數據

異動解讀 | Avalyn Pharma IPO首日盤中大漲44.44%

肺纖維化生物技術公司Avalyn Pharma IPO定價18美元募資3億，今晚登陸納斯達克

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.imtigers.com/hant/stock/AVLN"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"AVLN","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AVLN\",,,,,undefined,":{"symbol":"AVLN","market":"US","secType":"STK","nameCN":"Avalyn Pharma","latestPrice":34.98,"timestamp":1789416000000,"preClose":33.57,"halted":0,"volume":494137,"hourTrading":{"tag":"盘后","latestPrice":34.98,"preClose":34.98,"latestTime":"16:10 EDT","volume":6802,"amount":237933.96,"timestamp":1789416604308,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.0420017873100982,"floatShares":16666700,"shares":44333095,"eps":-2.33,"marketStatus":"盤後交易","change":1.41,"latestTime":"09-14 17:48:41 EDT","open":33.4,"high":36.42,"low":33.4,"amount":17331877,"amplitude":0.089961,"askPrice":36.5,"askSize":1,"bidPrice":34.4,"bidSize":1,"shortable":3,"etf":0,"ttmEps":-2.33,"tradingStatus":3,"nextMarketStatus":{"tag":"收盤","tradingStatus":0,"beginTime":1789430400000},"marketStatusCode":4,"adr":0,"listingDate":1777521600000,"exchange":"NASDAQ","adjPreClose":33.57,"preHourTrading":{"tag":"盘前","latestPrice":33.39,"preClose":33.57,"latestTime":"09:29 EDT","volume":3,"amount":100.17,"timestamp":1789392599504,"change":-0.18,"changeRate":-0.005362,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":34.98,"preClose":34.98,"latestTime":"16:10 EDT","volume":6802,"amount":237933.96,"timestamp":1789416604308,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":2.530952,"impliedVol":0.6676,"impliedVolPercentile":0.6875},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AVLN\",,,,,undefined,":{"symbol":"AVLN","floatShares":16666700,"roa":"-41.74%","roe":"-68.34%","lyrEps":-87.743381,"volumeRatio":2.530952,"shares":44333095,"dividePrice":0,"high":36.42,"amplitude":0.089961,"preClose":33.57,"low":33.4,"week52Low":24.15,"pbRate":"3.89","week52High":40.17,"institutionHeld":0,"latestPrice":34.98,"eps":-2.33,"divideRate":0,"volume":494137,"delay":0,"ttmEps":-2.33,"open":33.4,"prevYearClose":18,"prevWeekClose":33.57,"prevMonthClose":34.73,"prevQuarterClose":32.92,"fiveDayClose":37.39,"twentyDayClose":39.25,"sixtyDayClose":29.31},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/AVLN\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-12","symbol":"AVLN","fiscalQuarterEnding":"2026/06","expectedEps":-1.03,"name":null,"time":"盤前","type":"earning","dateTimestamp":1786507200000,"reportTimeType":"pre","actualEps":-0.98}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"AVLN\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"AVLN\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.5,"buy":0.5,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.5,"analysts":4,"updateTime":1781928000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/AVLN\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"AVLN","date":"2026-09-11","current":-15.012876,"percent":0.340659,"low":-16.842577,"twenty":-15.620135,"median":-14.133223,"eighty":-13.26914,"high":-8.833116,"avg":-14.352466,"sd":1.296311,"marketCap":1537028403},"quantilePoints":[{"date":"2026-05-01","current":-14.471589,"twenty":-13.343894,"median":-11.652352,"eighty":-9.960811,"marketCap":1233037266},{"date":"2026-05-08","current":-13.215324,"twenty":-14.430368,"median":-13.598092,"eighty":-13.264397,"marketCap":1125998425},{"date":"2026-05-15","current":-15.026112,"twenty":-14.666899,"median":-14.368536,"eighty":-13.42143,"marketCap":1280284879},{"date":"2026-05-22","current":-13.941602,"twenty":-14.643344,"median":-13.941602,"eighty":-13.42143,"marketCap":1187880255},{"date":"2026-05-29","current":-13.931787,"twenty":-14.643344,"median":-13.931787,"eighty":-13.215324,"marketCap":1187044014},{"date":"2026-06-05","current":-13.244767,"twenty":-14.510847,"median":-13.774754,"eighty":-13.102456,"marketCap":1128507148},{"date":"2026-06-12","current":-13.774754,"twenty":-14.471589,"median":-13.774754,"eighty":-13.161343,"marketCap":1173664159},{"date":"2026-06-18","current":-14.383258,"twenty":-14.479441,"median":-13.794383,"eighty":-13.204528,"marketCap":1225511097},{"date":"2026-06-26","current":-13.585419,"twenty":-14.649233,"median":-13.936694,"eighty":-13.238878,"marketCap":1284773093},{"date":"2026-07-02","current":-14.143275,"twenty":-14.655122,"median":-14.03484,"eighty":-13.265378,"marketCap":1337529476},{"date":"2026-07-10","current":-13.557292,"twenty":-14.643344,"median":-13.937009,"eighty":-13.265378,"marketCap":1282113107},{"date":"2026-07-17","current":-12.038425,"twenty":-14.576758,"median":-13.784568,"eighty":-13.15846,"marketCap":1138473879},{"date":"2026-07-24","current":-13.937009,"twenty":-14.519455,"median":-13.774754,"eighty":-13.193732,"marketCap":1318022914},{"date":"2026-07-31","current":-13.740119,"twenty":-14.495144,"median":-13.755125,"eighty":-13.157019,"marketCap":1299403014},{"date":"2026-08-07","current":-15.329303,"twenty":-14.523759,"median":-13.762486,"eighty":-13.165961,"marketCap":1449692206},{"date":"2026-08-14","current":-15.696852,"twenty":-14.725787,"median":-13.774754,"eighty":-13.189862,"marketCap":1621704615},{"date":"2026-08-21","current":-15.932863,"twenty":-15.087944,"median":-13.934398,"eighty":-13.227101,"marketCap":1646087817},{"date":"2026-08-28","current":-15.666815,"twenty":-15.573456,"median":-13.941602,"eighty":-13.249768,"marketCap":1618601298},{"date":"2026-09-04","current":-15.207667,"twenty":-15.433025,"median":-14.088821,"eighty":-13.261019,"marketCap":1571164886},{"date":"2026-09-11","current":-14.877252,"twenty":-15.620135,"median":-14.133223,"eighty":-13.26914,"marketCap":1537028403}],"updateTime":1789422521965},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"AVLN\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1150445147","title":"Avalyn完成AP01（吸入性吡非尼酮）針對進展性肺纖維化患者的2b期Mist試驗目標入組","url":"https://stock-news.laohu8.com/highlight/detail?id=1150445147","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1150445147?lang=zh_tw&edition=fundamental","pubTime":"2026-06-17 20:01","pubTimestamp":1781697684,"startTime":"0","endTime":"0","summary":"Avalyn Pharma宣布，其针对进展性肺纤维化患者研发的药物AP01（吸入性吡非尼酮）的2b期Mist临床试验，现已完成目标患者入组工作。这一关键里程碑标志着该试验已进入新的数据收集与分析阶段，为评估该吸入式疗法的有效性与安全性奠定了重要基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","AVLN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1199282092","title":"Avalyn Pharma 將公布AP01（吸入性吡非尼酮）治療肺纖維化的更多長期數據","url":"https://stock-news.laohu8.com/highlight/detail?id=1199282092","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1199282092?lang=zh_tw&edition=fundamental","pubTime":"2026-05-21 20:01","pubTimestamp":1779364877,"startTime":"0","endTime":"0","summary":"Avalyn Pharma宣布，关于其吸入性吡非尼酮（AP01）用于治疗肺纤维化的更多长期研究数据，将于2026年欧洲风湿病联盟大会上公布。这些数据有望进一步验证该疗法的长期疗效与安全性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVLN","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197256686","title":"異動解讀 | Avalyn Pharma IPO首日盤中大漲44.44%","url":"https://stock-news.laohu8.com/highlight/detail?id=1197256686","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1197256686?lang=zh_tw&edition=fundamental","pubTime":"2026-05-01 01:26","pubTimestamp":1777570002,"startTime":"0","endTime":"0","summary":"Avalyn Pharma今日盘中大涨44.44%，引起了市场的广泛关注。消息面上，Avalyn Pharma是一家专注于开发治疗罕见呼吸系统疾病吸入式药物的生物技术公司，其于今日正式在纳斯达克全球精选市场挂牌交易。这两款药物分别为吡非尼酮和尼达尼布的吸入制剂，针对特发性肺纤维化等疾病，旨在提升疗效并减少副作用。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["AVLN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631507639","title":"肺纖維化生物技術公司Avalyn Pharma IPO定價18美元募資3億，今晚登陸納斯達克","url":"https://stock-news.laohu8.com/highlight/detail?id=2631507639","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631507639?lang=zh_tw&edition=fundamental","pubTime":"2026-04-30 15:07","pubTimestamp":1777532834,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，Avalyn Pharma是一家处于二期临床试验阶段的生物技术公司，专注于开发治疗罕见呼吸系统疾病的吸入式药物。Avalyn的股票预计于4月30日(周四)正式在纳斯达克全球精选市场挂牌交易。作为临床阶段的生物技术企业，Avalyn Pharma致力于研发针对罕见呼吸系统疾病的吸入式抗纤维化疗法。其核心候选药物AP01和AP02分别为吡非尼酮和尼达尼布的吸入制剂，旨在将已获批的抗纤维化药物直接递送至肺部，提升局部药物暴露量并减少全身性副作用。","market":"us","thumbnail":"https://static.tigerbbs.com/6b69e234a63c2c0a69ccede7b0faaa18","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/6b69e234a63c2c0a69ccede7b0faaa18"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1437125.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1147","QQQA","PSQ","QDTE","FTEC","QQQM","QQQJ","IYW","BK4007","SQQQ","MNQmain","QID","QQQ","GPIQ","ONEQ","QQQE","AVLN","TQQQ","QYLG","QLD","QQQY","JEPQ","NVIW.SI","TQQY"],"isVideo":false,"video":null,"gpt_icon":1}],"pageSize":4,"totalPage":2,"pageCount":1,"totalSize":6,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/AVLN\",params:#limit:6,delay:false,,,undefined,":[]}}